CUSIP 761330109COMRVNCEURQ1 2025
58 filings · latest May 15, 2025
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Dekabank Deutsche Girozentrale | 86.1K | $425 |
| 4 | Feb 13, 2025 | Patrick Lee, Md | 13G/A | 11.0% | 1.61M | SEC |
| 5 | Feb 11, 2025 | Jpmorgan Chase &Amp; Co. | 13G | 5.4% | 5.69M | SEC |
| 6 | Feb 6, 2025 | Glazer Capital, LLC | 13G | 6.9% | 7.21M | SEC |
| 7 | Jan 30, 2025 | Teoxane SA | 13D/A | 6.2% | — | SEC |
| 8 | Jan 10, 2025 | Beryl Capital Management LLC | 13G | 6.1% | — | SEC |
| 9 | Jan 6, 2025 | Teoxane SA | 13D/A | 6.2% | — | SEC |
| 10 | Dec 19, 2024 | Teoxane SA | 13D/A | 6.2% | — | SEC |
See the full Schedule 13D/13G history for Revance Therapeutics Inc.
Unlock full history